drugset / Trial / NCT04573322
Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) Infected Subjects
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will assess the safety and efficacy of TSC as a treatment for participants who are infected with SARS-CoV-2 (COVID-19).
Timeline
- Start
- 2020-09-10
- Primary completion
- 2021-03-17
- Completion
- 2021-04-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trans Sodium Crocetinate | Other / unclassified | 0.25 mg/kg | Intravenous |
| Subject | Trans Sodium Crocetinate | Other / unclassified | 0.5 mg/kg | Intravenous |
| Subject | Trans Sodium Crocetinate | Other / unclassified | 1 mg/kg | Intravenous |
| Subject | Trans Sodium Crocetinate | Other / unclassified | 1.5 mg/kg | Intravenous |